COMBINE 2

 

Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor

 

 

Indication: Treatment naïve patients or switching option for patients with HIV RNA suppression on current treatment or second line treatment for patients with virological failure on prior treatment

 

Phase: IV

 

Countries:  UK, France, Belgium, Spain, Italy, Poland & Portugal

​

Sites:26

 

Status: Closed to Recruitment

​

Poster: EACS 2021

BHIVA 2022

IAS 2023

Abstract presented as poster at EACS 2023 - Dolutegravir + lamivudine 2-drug regimen is highly effective and well-tolerated in a real-world clinical setting in Europe: data from the COMBINE-2 Study